Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 2/20 | 0.42 |
| ▸ | CNR2 | P34972 | 2/20 | 0.42 |
| ▸ | ACE | P12821 | 7/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1954186 | 1.00 | CNR1 (0.42) | CNR1CNR2ACE | |
| SCHEMBL15665698 | 1.00 | CNR1 (0.42) | CNR1CNR2ACE | |
| SCHEMBL9107688 | 0.98 | ACE (0.41) | CNR1CNR2ACE | |
| SCHEMBL1952767 | 0.98 | ACE (0.41) | CNR1CNR2ACE | |
| SCHEMBL11098876 | 0.96 | CNR2 (0.40) | CNR1CNR2ACE | |
| SCHEMBL3718206 | 0.94 | CNR2 (0.40) | CNR1CNR2ACE | |
| SCHEMBL28152132 | 0.94 | ACE (0.43) | CNR1CNR2ACE | |
| SCHEMBL3718209 | 0.94 | CNR2 (0.40) | CNR1CNR2ACE | |
| SCHEMBL28152243 | 0.94 | ACE (0.43) | CNR1CNR2ACE | |
| SCHEMBL2223045 | 0.94 | ACE (0.43) | CNR1CNR2ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4153310-A1 | BBETA-15-42 FOR THE TREATMENT OF VIRAL ENDOTHELITIS | F4 Pharma GmbH (AT) | 2023-03-29 | — | — | EP | disclosed |
| WO-2021233971-A1 | BBETA-15-42 FOR THE TREATMENT OF VIRAL ENDOTHELITIS | Johann Wolfgang Goethe-Universität Frankfurt am Main (DE) | 2021-11-25 | — | — | WO | disclosed |
| US-8629157-B2 | Pyrrolidine compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-14 | — | — | US | disclosed |
| US-20130316945-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-11-28 | — | — | US | disclosed |
| US-8426359-B2 | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-04-23 | — | — | US | disclosed |
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
| CN-101462996-B | Preparation of 4-cyclohexyl proline derivative | SHANGHAI INST PHARM INDUSTRY | 2011-04-20 | — | — | CN | disclosed |
| US-7906550-B2 | Viricide against hepatitis virus; pyrrole derivatives as, for example, 3-acetyl-4,5-dimethyl-2-pyrrole carboxylic acid | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-15 | — | — | US | disclosed |
| US-20090291902-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED | 2009-11-26 | — | — | US | disclosed |
| CN-101462996-A | Preparation of 4-cyclohexyl proline derivative | SHANGHAI INST PHARM INDUSTRY (CN) | 2009-06-24 | — | — | CN | disclosed |
| US-20050119189-A1 | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease | VERTEX PHARMACEUTICALS INCORPORATED | 2005-06-02 | — | — | US | disclosed |
| US-20050080017-A1 | Inhibitors of serine proteases, particularly HVC NS3-NS4A protease | VERTEX PHARMACEUTICALS INCORPORATED | 2005-04-14 | — | — | US | disclosed |
| WO-2005028502-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE | VERTEX PHARMACEUTICALS, INCORPORATED (US) | 2005-03-31 | — | — | WO | disclosed |
| WO-2004092161-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2004-10-28 | — | — | WO | disclosed |
| US-6468977-B1 | COMPOUNDS USEFUL IN TREATMENT TREATMENT OF DISORDER AND/OR DISEASE CAUSED BY ACTIVITY OF ENZYMES SUCH AS HUMAN RHINOVIRUS 3C PROTEASE, TRANSGLUTAMINASE AND CATHEPSINS | APOTEX INC. (CA) | 2002-10-22 | — | — | US | disclosed |
| WO-2001090095-A1 | THIADIAZOLE COMPOUNDS USEFUL AS INHIBITORS OF CYSTEINE ACTIVITY DEPENDENT ENZYMES | APOTEX INC. (CA) | 2001-11-29 | — | — | WO | disclosed |
| US-6162791-A | Thiadiazole compounds useful as inhibitors of cysteine activity dependent enzymes | APOTEX INC. (CA) | 2000-12-19 | — | — | US | disclosed |
| EP-1058690-A1 | THIADIAZOLE COMPOUNDS USEFUL AS INHIBITORS OF CYSTEINE ACTIVITY DEPENDENT ENZYMES | APOTEX INC. (CA) | 2000-12-13 | — | — | EP | disclosed |
| WO-1999045027-A1 | THIADIAZOLE COMPOUNDS USEFUL AS INHIBITORS OF CYSTEINE ACTIVITY DEPENDENT ENZYMES | APOTEX INC. (CA) | 1999-09-10 | — | — | WO | disclosed |
| US-5059628-A | Proline or prolinol ester to enhance absorption | NITTO ELECTRIC INDUSTRIAL CO., LTD. (JP) | 1991-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | CNR1 2/4885CNR2 1/4885ACE 3990/4885 |
| US-20090291902-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE | PRSS1, SERPINB1, SPINT2 | CNR1 3157/4885CNR2 4217/4885ACE 34/4885 |
| US-20050119189-A1 | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease | PRSS1, SERPINB1, SPINT2 | CNR1 3157/4885CNR2 4217/4885ACE 34/4885 |
| US-20050080017-A1 | Inhibitors of serine proteases, particularly HVC NS3-NS4A protease | HPN, PRSS1, SERPINB1 | CNR1 3666/4885CNR2 4474/4885ACE 65/4885 |
| US-20130316945-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE | PRSS1, SERPINB1, SPINT2 | CNR1 3157/4885CNR2 4217/4885ACE 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.